Kura Oncology to Report Second Quarter 2024 Financial Results
Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. financial markets close. The company's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss the financial results and provide a corporate update.
Interested parties can access the live call by dialing (877) 300-8521 (domestic) or (412) 317-6026 (international). A live webcast and archived replay of the event will be available on the company's website at www.kuraoncology.com in the investor relations section.
Kura Oncology (Nasdaq: KURA), un'azienda biofarmaceutica in fase clinica focalizzata su medicinali di precisione per il trattamento del cancro, ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre 2024 giovedì 8 agosto 2024, dopo la chiusura dei mercati finanziari statunitensi. La direzione dell'azienda condurrà un webcast e una conferenza telefonica alle 16:30 ET / 13:30 PT nello stesso giorno per discutere dei risultati finanziari e fornire un aggiornamento aziendale.
Le parti interessate possono accedere alla chiamata dal vivo componendo (877) 300-8521 (nazionale) o (412) 317-6026 (internazionale). Un webcast dal vivo e una registrazione archiviata dell'evento saranno disponibili sul sito web dell'azienda all'indirizzo www.kuraoncology.com nella sezione relazioni con gli investitori.
Kura Oncology (Nasdaq: KURA), una empresa biofarmacéutica en etapa clínica centrada en medicamentos de precisión para el tratamiento del cáncer, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el jueves 8 de agosto de 2024, después del cierre de los mercados financieros en EE.UU. La dirección de la empresa llevará a cabo un webcast y una llamada de conferencia a las 4:30 p.m. ET / 1:30 p.m. PT el mismo día para discutir los resultados financieros y proporcionar una actualización corporativa.
Las partes interesadas pueden acceder a la llamada en vivo marcando (877) 300-8521 (nacional) o (412) 317-6026 (internacional). Un webcast en vivo y una repetición archivada del evento estarán disponibles en el sitio web de la empresa www.kuraoncology.com en la sección de relaciones con los inversores.
Kura Oncology (나스닥: KURA)는 암 치료를 위한 정밀 의약품에 집중하는 임상 단계의 생명공학 회사로, 2024년 2분기 재무 결과를 2024년 8월 8일 목요일에 미국 금융 시장 종료 후 발표할 것이라고 발표했습니다. 회사 경영진은 같은 날 오후 4시 30분 ET / 오후 1시 30분 PT에 재무 결과에 대해 논의하고 기업 업데이트를 제공하기 위해 웹캐스트와 전화 회의를 주최할 예정입니다.
관심 있는 분들은 (877) 300-8521 (국내) 또는 (412) 317-6026 (국제)로 전화를 걸어 라이브 통화에 참여할 수 있습니다. 라이브 웹캐스트와 이벤트의 아카이브 재생은 회사 웹사이트 www.kuraoncology.com의 투자자 관계 섹션에서 확인할 수 있습니다.
Kura Oncology (Nasdaq : KURA), une entreprise bio-pharmaceutique en phase clinique axée sur les médicaments de précision pour le traitement du cancer, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le jeudi 8 août 2024, après la fermeture des marchés financiers américains. La direction de l'entreprise animera un webinaire et une conférence téléphonique à 16h30 ET / 13h30 PT le même jour pour discuter des résultats financiers et fournir une mise à jour sur l'entreprise.
Les parties intéressées peuvent accéder à la conférence téléphonique en direct en composé le (877) 300-8521 (national) ou le (412) 317-6026 (international). Un webinaire en direct et une rediffusion archivée de l'événement seront disponibles sur le site web de l'entreprise à l'adresse www.kuraoncology.com dans la section des relations avec les investisseurs.
Kura Oncology (Nasdaq: KURA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf präzisionsmedizinische Therapien zur Krebsbehandlung konzentriert, hat angekündigt, dass es seine finanziellen Ergebnisse für das zweite Quartal 2024 am Donnerstag, den 8. August 2024, nach Schließung der US-Finanzmärkte veröffentlichen wird. Das Management des Unternehmens wird am selben Tag um 16:30 Uhr ET / 13:30 Uhr PT einen Webcast und eine Telefonkonferenz abhalten, um die finanziellen Ergebnisse zu besprechen und ein Unternehmensupdate bereitzustellen.
Interessierte Parteien können an dem Live-Anruf teilnehmen, indem sie (877) 300-8521 (inländisch) oder (412) 317-6026 (international) wählen. Ein Live-Webcast und eine archivierte Wiederholung der Veranstaltung werden auf der Unternehmenswebsite unter www.kuraoncology.com im Bereich für Investoren zur Verfügung stehen.
- None.
- None.
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2024 financial results after the close of U.S. financial markets on Thursday, August 8, 2024. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing (877) 300-8521 for domestic callers and (412) 317-6026 for international callers. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Contacts
Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com
Media:
Alexandra Weingarten
Associate Director, Investor Relations &
Corporate Communications
(858) 500-8822
alexandra@kuraoncology.com
FAQ
When will Kura Oncology (KURA) report its Q2 2024 financial results?
How can investors access Kura Oncology's (KURA) Q2 2024 earnings call?
What time is Kura Oncology's (KURA) Q2 2024 earnings call scheduled for?
Where can I find the replay of Kura Oncology's (KURA) Q2 2024 earnings call?
